Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis

Company Overview

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Key Stats

• Today's Range: $29.79 to $29.79
• 50-Day Range: $27.06 to $31.99
• 52-Week Range: $24.08 to $32.25
• Volume: N/A
• Average Volume: 65 shs
• Market Capitalization: $10.61 billion
• P/E Ratio: 25.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

BIOVF Stock Analysis - Frequently Asked Questions

How have BIOVF shares performed this year?

Swedish Orphan Biovitrum's stock was trading at $27.66 at the beginning of 2025. Since then, BIOVF stock has increased by 7.7% and is now trading at $29.79.

How were Swedish Orphan Biovitrum's earnings last quarter?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) announced its quarterly earnings results on Wednesday, July, 16th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. The firm had revenue of $649.61 million for the quarter, compared to analyst estimates of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a trailing twelve-month return on equity of 11.67%.

How do I buy shares of Swedish Orphan Biovitrum?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/16/2025
• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOVF
• CIK: N/A
• Web: www.sobi.com
• Phone: (468) 697-2000
• Fax: N/A
• Employees: 1,772
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): $1.19
• Trailing P/E Ratio: 25.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $367.52 million
• Net Margins: 16.05%
• Pretax Margin: 18.72%
• Return on Equity: 11.67%
• Return on Assets: 6.34%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 1.00
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $2.46 billion
• Price / Sales: 4.31
• Cash Flow: $2.05 per share
• Price / Cash Flow: 14.52
• Book Value: $11.36 per share
• Price / Book: 2.62

Miscellaneous

• Outstanding Shares: 356,000,000
• Free Float: N/A
• Market Cap: $10.61 billion
• Optionable: Not Optionable
• Beta: 0.46